Silence provided a corporate update with its H120 financial results that show it moving forward on all fronts. It announced that it has hired a new CEO, listed its stock on Nasdaq, enrolled its first volunteers in SLN124’s Phase I study, filed its SLN360 IND ahead of schedule and expanded its existing partnership with Mallinckrodt, all in the past few weeks.
17 Sep 2020
Silence Therapeutics - Change is good
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Silence Therapeutics - Change is good
Silence Therapeutics plc (SLNCF:OTC) | 0 0 0.0%
- Published:
17 Sep 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
6
Silence provided a corporate update with its H120 financial results that show it moving forward on all fronts. It announced that it has hired a new CEO, listed its stock on Nasdaq, enrolled its first volunteers in SLN124’s Phase I study, filed its SLN360 IND ahead of schedule and expanded its existing partnership with Mallinckrodt, all in the past few weeks.